Literature DB >> 12478013

Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy.

Claude Koren1, Rinat Yerushalmi, Alan Katz, Hana Malik, Aaron Sulkes, Eyal Fenig.   

Abstract

Hypersensitivity reactions to intravenous cisplatin are rare. The appearance of hypersensitivity reactions in 4 of 25 consecutive patients treated with concomitant pelvic radiation and weekly intravenous cisplatin for gynecologic malignancies is reported. The reactions appeared within hours of cisplatin delivery and included primarily fever, rash, and pruritus. Infection was ruled out by blood cultures and other laboratory studies. Affected patients were treated prophylactically with an antihistamine before subsequent courses of cisplatin, with excellent results. The high rate of hypersensitivity reactions in our series may be attributable to tumor necrosis and cytokine release caused by the pelvic irradiation. Clinicians should be aware of this potential side effect so that early premedication regimens can be instituted to prevent unnecessary toxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478013     DOI: 10.1097/00000421-200212000-00020

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  10 in total

1.  Platin chemotherapy hypersensitivity reactions: Expanding the scope of practice and improving care.

Authors:  Amy S Levin; Gita Bhattacharya; Kimberly Blumenthal; Carlos A Camargo; Aleena Banerji
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-19

Review 2.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 3.  Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

Authors:  Joana Caiado; Mariana Castells
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

4.  Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.

Authors:  Qiuyan Song; Yuanxuan Cai; Kangyuan Guo; Min Li; Zaoqin Yu; Qirui Tai; Yuhang Zhao; Xuan Zhu; Chengliang Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

5.  Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors.

Authors:  Xiaolin Ma; Xiuqin Li
Journal:  Int J Clin Oncol       Date:  2018-08-04       Impact factor: 3.402

6.  Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction.

Authors:  M Wasif Saif; Shailja Roy; Leslie Ledbetter; Jennifer Madison; Kostas Syrigos
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

8.  Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.

Authors:  Yoshihiro Shibata; Hiroshi Ariyama; Eishi Baba; Yasushi Takii; Taito Esaki; Kenji Mitsugi; Tanji Tsuchiya; Hitoshi Kusaba; Koichi Akashi; Shuji Nakano
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

9.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

Review 10.  Hypersensitivity Reactions to Platinum Agents and Taxanes.

Authors:  Lulu R Tsao; Fernanda D Young; Iris M Otani; Mariana C Castells
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-02       Impact factor: 10.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.